The New Zealand medical journal · 1998
Hepatitis B virus carrier prevalence in New Zealand: population estimates using the 1987 police and customs personnel survey.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blakely T, Salmond C, Tobias M
Аннотация
AIM: To estimate the population hepatitis B surface antigen (HBsAg) carrier prevalence for adults in New Zealand.
METHOD: Data for 1987 from the New Zealand Police Department and New Zealand Customs Department hepatitis B sero-marker survey were further analysed. The sample size was 5510 staff who had completed a questionnaire, had blood sera taken and were not already immunised against hepatitis B.
RESULTS: Maori adults had a HBsAg carrier prevalence of 5.43% (95% confidence interval 3.07-8.81), Pacific adults 4.44% (1.65-9.42), and European adults 0.42% (0.26-0.65). Other ethnic minorities and people with two or more self-assigned ethnic identities had a carrier prevalence of 3.85% (1.06-9.56). There were non-significant differences in this study for carrier prevalence by sex, age and region.
CONCLUSIONS: Policy formation on screening programmes for hepatitis B carriers should assume a HBsAg carrier prevalence of about 5% for Maori, Pacific people and ethnic minorities, and about 0.5% for New Zealanders of European extraction.
METHOD: Data for 1987 from the New Zealand Police Department and New Zealand Customs Department hepatitis B sero-marker survey were further analysed. The sample size was 5510 staff who had completed a questionnaire, had blood sera taken and were not already immunised against hepatitis B.
RESULTS: Maori adults had a HBsAg carrier prevalence of 5.43% (95% confidence interval 3.07-8.81), Pacific adults 4.44% (1.65-9.42), and European adults 0.42% (0.26-0.65). Other ethnic minorities and people with two or more self-assigned ethnic identities had a carrier prevalence of 3.85% (1.06-9.56). There were non-significant differences in this study for carrier prevalence by sex, age and region.
CONCLUSIONS: Policy formation on screening programmes for hepatitis B carriers should assume a HBsAg carrier prevalence of about 5% for Maori, Pacific people and ethnic minorities, and about 0.5% for New Zealanders of European extraction.